LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 118

Search options

  1. Article ; Online: Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis.

    Witteles, Ronald M

    JACC. CardioOncology

    2021  Volume 3, Issue 4, Page(s) 516–521

    Language English
    Publishing date 2021-10-19
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2666-0873
    ISSN (online) 2666-0873
    DOI 10.1016/j.jaccao.2021.05.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?

    Witteles, Ronald M / Reddy, Sunil A

    JACC. CardioOncology

    2022  Volume 5, Issue 1, Page(s) 133–136

    Language English
    Publishing date 2022-12-06
    Publishing country United States
    Document type Editorial
    ISSN 2666-0873
    ISSN (online) 2666-0873
    DOI 10.1016/j.jaccao.2022.10.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time.

    Witteles, Ronald M

    Journal of cardiac failure

    2019  Volume 25, Issue 3, Page(s) 154–155

    MeSH term(s) Amyloid Neuropathies, Familial ; Doxycycline ; Heart Failure ; Humans ; Prealbumin ; Ursodeoxycholic Acid
    Chemical Substances Prealbumin ; Ursodeoxycholic Acid (724L30Y2QR) ; Doxycycline (N12000U13O)
    Language English
    Publishing date 2019-02-03
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1281194-4
    ISSN 1532-8414 ; 1071-9164
    ISSN (online) 1532-8414
    ISSN 1071-9164
    DOI 10.1016/j.cardfail.2019.01.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Global Longitudinal Strain in Cardio-Oncology.

    Moslehi, Javid J / Witteles, Ronald M

    Journal of the American College of Cardiology

    2021  Volume 77, Issue 4, Page(s) 402–404

    MeSH term(s) Cardiotoxicity/etiology ; Humans ; Medical Oncology ; Neoplasms/epidemiology ; Neoplasms/therapy
    Language English
    Publishing date 2021-01-28
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 605507-2
    ISSN 1558-3597 ; 0735-1097
    ISSN (online) 1558-3597
    ISSN 0735-1097
    DOI 10.1016/j.jacc.2020.12.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.

    Witteles, Ronald M / Liedtke, Michaela

    Circulation. Heart failure

    2021  Volume 14, Issue 4, Page(s) e008225

    MeSH term(s) Biomarkers/blood ; Cardiomyopathies/blood ; Cardiomyopathies/diagnostic imaging ; Humans ; Immunoglobulin Light Chains/blood ; Immunoglobulin Light-chain Amyloidosis/blood ; Immunoglobulin Light-chain Amyloidosis/diagnostic imaging ; Radionuclide Imaging/methods
    Chemical Substances Biomarkers ; Immunoglobulin Light Chains
    Language English
    Publishing date 2021-03-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2429459-7
    ISSN 1941-3297 ; 1941-3289
    ISSN (online) 1941-3297
    ISSN 1941-3289
    DOI 10.1161/CIRCHEARTFAILURE.120.008225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reply: Should We Be for ASCT?: If Yes, Then When?

    Witteles, Ronald M / Barrett, Christopher D

    JACC. Heart failure

    2020  Volume 8, Issue 8, Page(s) 696–697

    MeSH term(s) Amyloidosis ; Heart Failure ; Heart Transplantation ; Humans ; Stem Cell Transplantation ; Transplantation, Autologous
    Language English
    Publishing date 2020-09-26
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2705621-1
    ISSN 2213-1787 ; 2213-1779
    ISSN (online) 2213-1787
    ISSN 2213-1779
    DOI 10.1016/j.jchf.2020.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis: Still Much to Learn.

    Alexander, Kevin M / Witteles, Ronald M

    JACC. Cardiovascular imaging

    2020  Volume 13, Issue 6, Page(s) 1322–1324

    MeSH term(s) Amyloid Neuropathies, Familial/diagnostic imaging ; Humans ; Mutation ; Prealbumin/genetics ; Radionuclide Imaging
    Chemical Substances Prealbumin
    Language English
    Publishing date 2020-01-15
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2491503-8
    ISSN 1876-7591 ; 1936-878X
    ISSN (online) 1876-7591
    ISSN 1936-878X
    DOI 10.1016/j.jcmg.2019.11.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies.

    Witteles, Ronald M

    Journal of cardiac failure

    2016  Volume 22, Issue 6, Page(s) 459–464

    Abstract: Background: Cardiac biomarkers have been extensively investigated as early detectors of cardiac toxicity from cancer therapies. Whereas the role of biomarkers in monitoring anthracycline toxicity is generally well understood, substantial uncertainty ... ...

    Abstract Background: Cardiac biomarkers have been extensively investigated as early detectors of cardiac toxicity from cancer therapies. Whereas the role of biomarkers in monitoring anthracycline toxicity is generally well understood, substantial uncertainty remains regarding their role in monitoring newer targeted cancer therapies.
    Methods and results: This review article examines all major published studies using cardiac troponins and/or N-terminal pro-B-type natriuretic peptide (NT-proBNP) in monitoring for cardiac toxicity with trastuzumab, tyrosine kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. There is substantial variability among studies regarding biomarker assays used, sensitivity of the assays, and definitions of abnormal results. In general, troponin I predicts early but not late cardiac events when trastuzumab is administered after anthracyclines, but troponin increases likely reflect anthracycline injury rather than trastuzumab injury. NT-proBNP detects cardiac toxicity with tyrosine kinase inhibitors and mTOR inhibitors, but not independently from echocardiography.
    Conclusions: Troponin I can serve as a marker for susceptibility to cardiac toxicity during early trastuzumab treatment in patients who have received recent anthracyclines. NT-proBNP can serve as a useful marker of cardiac toxicity in patients treated with tyrosine kinase inhibitors or mTOR inhibitors if echocardiographic screening is not being used.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Biomarkers/blood ; Cardiomyopathies/blood ; Cardiomyopathies/chemically induced ; Cardiotoxicity ; Humans ; Natriuretic Peptide, Brain/blood ; Neoplasms/drug therapy ; Troponin I/blood
    Chemical Substances Antineoplastic Agents ; Biomarkers ; Troponin I ; Natriuretic Peptide, Brain (114471-18-0)
    Language English
    Publishing date 2016-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1281194-4
    ISSN 1532-8414 ; 1071-9164
    ISSN (online) 1532-8414
    ISSN 1071-9164
    DOI 10.1016/j.cardfail.2016.03.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Developing Therapy for Transthyretin Amyloidosis.

    Campbell, Courtney M / Zhang, Kathleen / Lenihan, Daniel J / Witteles, Ronald

    The American journal of medicine

    2022  Volume 135 Suppl 1, Page(s) S44–S48

    Abstract: Transthyretin amyloidosis (ATTR) is an under-recognized cause of cardiomyopathy and neuropathy. Until recently, there were limited therapeutic options for ATTR. However, new therapeutics, including tafamidis, patisiran, and inotersen, increase both ... ...

    Abstract Transthyretin amyloidosis (ATTR) is an under-recognized cause of cardiomyopathy and neuropathy. Until recently, there were limited therapeutic options for ATTR. However, new therapeutics, including tafamidis, patisiran, and inotersen, increase both quality and length of life in patients with ATTR. This review details the chronological development of ATTR therapies through landmark clinical trials. In addition, we discuss emerging ATTR therapies including improvements in drug delivery methods, antibodies to break down deposited amyloid fibrils, and gene editing. ATTR is a prime example of how an understanding of the pathophysiological basis of disease can lead to effective therapies. The future of ATTR therapy is bright, with every reason to believe outcomes will continue to improve.
    MeSH term(s) Amyloid Neuropathies, Familial/drug therapy ; Amyloid Neuropathies, Familial/genetics ; Cardiomyopathies/drug therapy ; Humans ; Prealbumin/genetics
    Chemical Substances Prealbumin
    Language English
    Publishing date 2022-01-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2022.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.

    Witteles, Ronald M / Liedtke, Michaela

    JACC. CardioOncology

    2019  Volume 1, Issue 1, Page(s) 117–130

    Abstract: AL amyloidosis results from clonal production of immunoglobulin light chains, most commonly arising from a clonal plasma cell disorder. Once considered a nearly uniformly fatal disease, prognosis has improved markedly over the past 15 years, ... ...

    Abstract AL amyloidosis results from clonal production of immunoglobulin light chains, most commonly arising from a clonal plasma cell disorder. Once considered a nearly uniformly fatal disease, prognosis has improved markedly over the past 15 years, predominantly because of advances in light chain suppressive therapies. Cardiac deposition of amyloid fibrils is common, and the severity of cardiac involvement remains the primary driver of prognosis. Improvements in chemotherapy/immunotherapy have prompted a reassessment of the role of advanced cardiac therapies previously considered contraindicated in most patients, including the role of implantable cardioverter-defibrillators and cardiac transplantation. This state-of-the-art review highlights the current state of the field, including diagnosis, prognosis, and hematologic- and cardiac-specific therapies.
    Language English
    Publishing date 2019-09-24
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2666-0873
    ISSN (online) 2666-0873
    DOI 10.1016/j.jaccao.2019.08.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top